is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (to A.M.), CPRIT Core Facilities Support Grant RP170691 (to M.T.L.), and a gift from the Korell family for the study of triple negative breast cancer. ...
What stage is my cancer? Has it spread to lymph nodes (glands near the breast) or other areas? Should I havechemotherapybefore or after surgery? What type of surgery will I need? Will I need radiation treatments? Triple-Negative Breast Cancer Treatment ...
C. DangA.E. GiulianoS. KarlanElsevier BVInternational Journal of Radiation Oncology*Biology*PhysicsClinicalTrials.gov (2015) Neoadjuvant MEDI4736 concomitant with weekly nab-paclitaxel and dose-dense AC for stage I-III triple negative breast cancer. https://clinicaltrials.gov/ct2/show/ NCT02489448...
This study of patients with early-stage triple-negative breast cancer not treated with adjuvant or neoadjuvant chemotherapy analyzes the association
Triple-negative breast cancers are defined as lacking expression of the ER, PgR, and HER-2 receptors.116They are usually associated with a high histological grade117and are recognised to have a more aggressive natural history than other breast cancer subtypes. Although considered as one group, the...
Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data. J Clin Oncol. 2018;36(15 suppl):1012.Google ScholarCrossref 35. Loibl S, Untch M, Burchardi N, et al. ...
early stagetriple-negative breast cancerde-escalationpersonalizationbiomarkersimmunotherapyquality of lifeTriple-negative breast cancer (TNBC) accounts for approximately 15%-20% of breast cancers diagnosed worldwide, which amounts to almost 200000 cases each year. Although historically TNBC is considered ...
Indiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and which women are likely to remain disease-free. They will present their findings on December 13, 2019, at the San Antoni
Triple-Negative Breast Cancer Some breast cancers -- between 10% and 20% -- are known as “triple negative” because they don’t have estrogen and progesterone receptors and don’t overexpress the HER2 protein. Many breast cancers associated with the gene BRCA1 are triple negative. They are ...
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of ...